|
|
|
|
| Advertisement |
E-Book: A High-Touch Approach to Product Access
The commercial success of bringing a new pharmaceutical to market begins with the patient. Knowledge of the patient experience combined with therapeutic area expertise helps anticipate challenges in the treatment journey.
Explore how taking a high-touch approach to commercialization can improve product access. Sponsored by AmerisourceBergen
 Learn more
|
|
| Industry update |
| //Kymab (Cambridge, UK) appointed Dr. Arndt Schottelius as its first Executive Vice President Research & Development. //Summit Therapeutics (Oxford, UK) appointed Dr. David Roblin as Chief Operating Officer and President of Research and Development.//Dr. George Gunn, former CEO of Novartis Animal Health, was appointed as Chairman at ViroVet (Leuven, Belgium). //Avadel Pharmaceuticals (Dublin, Ireland) appointed Gregory J. Divis to the newly created role of Executive Vice President and Chief Commercial Officer.//Basilea Pharmaceutica Ltd. (Basel, Switzerland) reported that Ursula Eberhardt will take the role of Head of Global Human Resources and join the Extended Management Committee.// |
|
ADVERTISEMENT
|
|
ADVERTISEMENT
|
|
|
|
|
| |
|
|
